Demo trial
Pro-Kids is a multi-center, double-blind, randomized and placebo-controlled intervention study in children with chronic kidney disease. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in CKD patients treated with hemodialysis.
What is FARI-DME-001 about?
In this study, doctors are testing a flexible schedule for an eye medication called faricimab. They want to see how it compares to another medication, aflibercept, in helping to improve or protect your vision. This trial is for people with Diabetic Macular Edema (DME) who have never had eye injections for it before.
What is Diabetic Macular Edema (DME) about?
Diabetic macular edema (DME) is a leading cause of vision loss for working-age adults with diabetes. It occurs when specific proteins in the body (known as VEGF-A and Ang-2) cause the delicate blood vessels in the retina to become unstable and leak fluid. Currently, the standard treatment involves regular eye injections—often every one to two months—to block these proteins and reduce the swelling. While these treatments are highly effective, the need for frequent clinic visits and injections can place a significant emotional, logistical, and financial strain on patients.
About this trial
On this webpage, you will learn about diabetic macular edema (DME) and a clinical trial for this condition. You can use the information on this webpage to help you talk with your doctor about whether this study is right for you.
What will happen to me in this trial?
If you join this 12-month study, you will first undergo a screening visit with eye and blood tests to ensure it is safe for you to participate.
If you join this 12-month study, you will first undergo a screening visit with eye and blood tests to ensure it is safe for you to participate. Once confirmed, you will be randomly assigned to receive eye injections of either faricimab or aflibercept. You will start with a few monthly injections, after which your doctor may extend the time between your treatments up to 16 weeks based on how well your eye responds. Throughout the year, you will attend regular clinic visits where the study team will closely monitor your vision, eye health, and overall well-being.
Arms and Interventions
Description
No prior chemotherapy for AML, except hydroxyurea for up to 14 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell [WBC] counts > 25x109/L); patients may have had previous treatment with erythroid stimulating agents (ESA) or hypomethylating agents (HMAs) for an antecedent phase of MDS; ESA and HMAs have to be stopped at least four weeks before start of study treatment.
Overview of the Study Procedures
Patient-VersionFaricimab (often known by its brand name, Vabysmo) is a prescription medication used to treat vision loss caused by conditions like diabetic macular edema. It works by targeting and blocking two different proteins in the eye that cause delicate blood vessels to become unstable and leak fluid. By blocking both of these proteins at the same time, the medication aims to reduce swelling more effectively, which may allow for a more flexible schedule and more time—up to 16 weeks—between your injection appointments...
About Faricimab
Patient-Version Faricimab (often known by its brand name, Vabysmo) is a prescription medication used to treat vision loss caused by conditions like diabetic macular edema. It works by targeting and blocking two different proteins in the eye that cause delicate blood vessels to become unstable and leak fluid.
How can I benefit from participating?
If you join this 12-month study, you will first undergo a screening visit with eye and blood tests to ensure it is safe for you to participate. Once confirmed, you will be randomly assigned to receive eye injections of either faricimab or aflibercept. You will start with a few monthly injections, after which your doctor may extend the time between your treatments up to 16 weeks based on how well your eye responds. Throughout the year, you will attend regular clinic visits where the study team will closely monitor your vision, eye health, and overall well-being.
Administrations of Paclitaxel
Patient Survey
Complete the survey to participate in a clinical trial